编者按:本文来自米内网,作者苍穹;赛柏蓝转载,编辑晓琳近日,西藏自治区医院发布公告称,拟引进36款新药以满足临床用药需求。其中,独家品种(含剂型独家,下同)占比超35%,包括地达西尼胶囊、递法明片等2025H1在中国公立医疗机构终端销售额增速均达两位数及以上的潜力品种;12款国采品种在列,仅集采中选企业允许申报。此次拟进院新药包含27款化药、5款中成药和4款生物药;按治疗大类统计,神经系统药物、...
Source Link编者按:本文来自米内网,作者苍穹;赛柏蓝转载,编辑晓琳近日,西藏自治区医院发布公告称,拟引进36款新药以满足临床用药需求。其中,独家品种(含剂型独家,下同)占比超35%,包括地达西尼胶囊、递法明片等2025H1在中国公立医疗机构终端销售额增速均达两位数及以上的潜力品种;12款国采品种在列,仅集采中选企业允许申报。此次拟进院新药包含27款化药、5款中成药和4款生物药;按治疗大类统计,神经系统药物、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.